C.R. Bard's (BCR) solid performance in the Vascular, Urology and Surgical Specialties were the key highlights of the second quarter.
Align Technology (ALGN) rides high in Q2 banking on robust growth in the Invisalign space.
Zimmer Biomet's (ZBH) Q2 earnings results disappoint with an unimpressive Knee, Hip and Dental performances.
Boston Scientific's (BSX) Q2 results gain on balanced segmental growth. Currency remains a dampener though.
Strength in Hospice and Personal Care businesses offset the weakness in Amedisys' (AMED) Home Health Medicare business in Q2.
Edwards Lifesciences (EW) rides high on continued growth in its highly advanced Transcatheter Heart Valve space in Q2.
Merger activity is increasing, and investors need to be prepared. This podcast discusses the 'merger arbitrage' strategy and what you need to know about this approach.
Thermo Fisher Scientific (TMO) continues to gain considerable synergies from FEI Company acquisition. A raised guidance buoys optimism.
Arts theatre, LondonSandra Dickinson’s heroic portrayal of the once world-famous TV comedian brings a pulse to this stage corpseAt the height of her success, Lucille Ball was the most famous woman on the planet. A newspaper suggested that her face was more familiar to the American public than Jesus Christ’s. Idi Amin was a huge fan. Reruns of the self-produced sitcom I Love Lucy, in which she and her husband Desi Arnaz played Lucy and Ricky Ricardo, a version of themselves, were still being screened long after the final episode of the six-year-long series was broadcast in 1957. There were endless spinoffs, keeping Ball working well into her 70s. Ball was ahead of her time. Washed-up in the movies, she spotted the potential of TV long before others working in Hollywood. She kept control by self-producing, and the studio she founded, Desilu, spawned other hits, including Star Trek and Mission: Impossible. She filmed in front of a live audience. She was married to a Cuban during an era when tensions between the US and Cuba were rising. Continue reading...
Quest Diagnostics (DGX) continues to ride high on its advanced diagnostic offerings. Also, a raised view buoys optimism.
Despite an upbeat guidance, cutthroat competition in the niche space is likely to mar Ecolab's (ECL) growth in the second quarter.
The timing of Good Friday is likely to dampen sales at Henry Schein (HSIC) in second-quarter 2017. Meanwhile, geographic expansion should continue.
We believe Cerner's (CERN) strong sales performance, solid portfolio and strategic initiatives have positioned it for stellar growth.
Illumina (ILMN) is well poised to witness steady top-line growth in Q2. Yet, the bottom line may remain stressed.
The growing adoption of Stryker's (SYK) MAKO robots is expected to drive second-quarter 2017 sales in the orthopedic and reconstructive surgery market.
Currency headwind is likely to dampen ResMed's (RMD) gains in the COPD and sleep apnea market.
McKesson's (MCK) strategic acquisitions and promising guidance raise optimism for the first quarter of fiscal 2018.
IDEXX Laboratories' (IDXX) Companion Animal Group business might drive its performance in Q2.
Despite an upbeat guidance, cutthroat competition in the niche space is likely to mar Express Scripts' (ESRX) growth in the second quarter.
Despite an upbeat guidance, lower cyclophosphamide sales are likely to mar Baxter International (BAX) performance in the second quarter 2017.